The capital pricing nicotinamide mononucleotide as an aging drug in APAC points to the Washington University trial as its primary clinical evidence. Twenty-five postmenopausal women. Ten weeks. Skeletal muscle insulin sensitivity as the primary endpoint (Yoshino et al., Cell Metabolism, 2021), not biological age, not morbidity, not an outcome that licenses the anti-aging claims currently on retail in three APAC markets.

China's National Health Commission approved NMN as a novel food ingredient in 2022, a classification requiring safety evidence only, with no efficacy standard and no authorization for disease-prevention language. Japan's Consumer Affairs Agency processes NMN product claims through its Foods with Function Claims notification pathway, where the substantiation filings for leading brands cite the Yoshino 2021 paper alongside Igarashi et al. (2022), a study measuring plasma NAD+ elevation in older Japanese adults with no morbidity endpoint. Consumer retail pricing in mainland China runs between RMB 800 and RMB 2,400 per month per consumer. The capital is pricing an aging pharmaceutical. The regulatory pathway in both jurisdictions is a food safety notification. A family-office PM running due diligence on any NMN-focused vehicle currently seeking capital in Singapore would find, in the clinical data room: one completed RCT, n=25, primary investigator Samuel Klein at Washington University School of Medicine, published Cell Metabolism, 2021.